FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)

NCT03142516 PHASE2 COMPLETED

To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy. The clinical hypothesis of this study is that the combination of panitumumab and FOLFIRI is a good treatment option in elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC. Another purpose of this clinical trial is to determine the RAS/BRAF mutation status in liquid biopsies at baseline and at the time of disease progression.

Details

Lead sponsor	Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase	PHASE2
Status	COMPLETED
Enrolment	20
Start date	Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Neoplasms
• Colorectal Carcinoma
• Colorectal Cancer Metastatic
• Neoplasm Metastasis

Interventions

• Panitumumab
• Irinotecan
• Folinic acid
• 5-FU

Countries

Spain